Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Martin Hegen
Tanzania
Research Article
Attenuating Janus Kinases (JAK) by Tofacitinib Effectively Prevented Psoriasis Pathology in Various Mouse Skin Inflammation Models
Author(s): Hak-Ling Ma, Katherine Masek-Hammerman, Susan Fish, Lee Napierata, Eva Nagiec, Saifur Rahman, Martin Hegen and James D ClarkHak-Ling Ma, Katherine Masek-Hammerman, Susan Fish, Lee Napierata, Eva Nagiec, Saifur Rahman, Martin Hegen and James D Clark
Background: Tofacitinib is a Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK1 and JAK3 that blocks the signaling of type I interferons, IL-6 as well as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Together these cytokines are important to lymphocyte function and therefore regulate multiple aspects of the immune response. Tofacitinib has demonstrated efficacy in clinical trials of various autoimmune diseases including psoriasis.Objectives: To understand the mechanisms of action of tofacitinib in improving psoriasis.Methods: Tofacitinib was evaluated in several IL-23/Th17 pathway-dependent, psoriasis-like skin inflammation models.Results: We demonstrate that similar to mice that received mouse IL-12/23 p40 antibody (anti-p40), treatment with tofacitinib also reduced clinical sig.. View More»
DOI:
10.4172/2155-9899.1000176